Banson Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 1.00 M
as on 16-11-2024
- Company Age 29 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.68 Cr
as on 16-11-2024
- Satisfied Charges ₹ 6.20 Cr
as on 16-11-2024
- Revenue -4.54%
(FY 2023)
- Profit -19.62%
(FY 2023)
- Ebitda 24.08%
(FY 2023)
- Net Worth 12.94%
(FY 2023)
- Total Assets 28.01%
(FY 2023)
About Banson Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹6.68 Cr. The company has closed loans amounting to ₹6.20 Cr, as per Ministry of Corporate Affairs (MCA) records.
Santosh Bansal and Anish Bansal serve as directors at the Company.
- CIN/LLPIN
U24232PB1995PTC016354
- Company No.
016354
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 May 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Patiala, Punjab, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Banson Pharmaceuticals Private Limited offer?
Banson Pharmaceuticals Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Diclofenac.
Who are the key members and board of directors at Banson Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Santosh Bansal  | Director | 05-May-1995 | Current |
| Anish Bansal | Director | 02-Apr-2022 | Current |
Financial Performance of Banson Pharmaceuticals.
Banson Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 4.54% decrease. The company also saw a substantial fall in profitability, with a 19.62% decrease in profit. The company's net worth Soared by an impressive increase of 12.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Banson Pharmaceuticals?
In 2023, Banson Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 27 Jul 2024 | ₹1.50 Cr | Open |
Hdfc Bank Limited Creation Date: 07 Mar 2024 | ₹0.42 M | Open |
Axis Bank Limited Creation Date: 19 Jan 2024 | ₹3.50 Cr | Open |
How Many Employees Work at Banson Pharmaceuticals?
Unlock and access historical data on people associated with Banson Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Banson Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Banson Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
